Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.53 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621230 | 1.00 | GABBR2 (0.53) | GABBR2GABBR1TAAR1HTR2AEPHX1 | |
| SCHEMBL8810284 | 1.00 | GABBR2 (0.53) | GABBR2GABBR1TAAR1HTR2AEPHX1 | |
| Hydrochloric Acid SCHEMBL1983404 | 0.98 | GABBR2 (0.52) | GABBR2GABBR1TAAR1HTR2AEPHX1 | |
| SCHEMBL5308855 | 0.86 | ESR1 (0.55) | GABBR2GABBR1TAAR1ALDH1A1 | |
| SCHEMBL15903897 | 0.86 | ESR1 (0.55) | GABBR2GABBR1TAAR1SLC6A2 | |
| SCHEMBL5308356 | 0.86 | CHRNB2 (0.54) | GABBR2GABBR1TAAR1HTR2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL9735324 | 0.86 | CHRNB2 (0.55) | GABBR2GABBR1TAAR1HTR2AALDH1A1 | |
| SCHEMBL146771 | 0.85 | MTNR1A (0.55) | TAAR1EPHX1ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL10513800 | 0.85 | TAAR1 (0.47) | GABBR2GABBR1TAAR1HTR2AALDH1A1 | |
| SCHEMBL10269974 | 0.85 | LOXL2 (0.50) | GABBR2GABBR1TAAR1HTR2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372492-A1 | DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME | MISSISSIPPI STATE UNIVERSITY (US) | 2023-11-23 | — | — | US | claimed |
| EP-4221755-A1 | DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME | Mississippi State University (US) | 2023-08-09 | — | — | EP | claimed |
| WO-2022072425-A1 | DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME | PARK JOO YOUN (US) | 2022-04-07 | — | — | WO | claimed |
| CN-104081469-A | Electrically insulating oil composition having excellent performance in wide temperature range | JX NIPPON OIL & ENERGY CORP | 2014-10-01 | — | — | CN | claimed |
| CN-103582920-A | Electrical insulating oil composition having excellent low-temperature characteristics | JX NIPPON OIL & ENERGY CORP | 2014-02-12 | — | — | CN | claimed |
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | claimed |
| EP-2185560-A1 | HETEROARYL AMIDE ANALOGUES | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | claimed |
| WO-2009108551-A2 | HETEROARYL AMIDE ANALOGUES | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | claimed |
| WO-2009023623-A1 | HETEROARYL AMIDE ANALOGUES | H, LUNDBECK A/S (DK) | 2009-02-19 | — | — | WO | claimed |
| WO-1999055323-A1 | USE OF NMDA ANTAGONISTS FOR TREATMENT OF IRRITABLE BOWEL SYNDROME | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | claimed |
| WO-1999055322-A1 | USE OF NMDA ANTAGONISTS AND/OR SODIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | claimed |
| EP-0906275-A1 | NEW FORMS OF ORGANIC SALTS OF N'N-DIACETYLCYSTINE | Astra Aktiebolag (publ) (SE) | 1999-04-07 | — | — | EP | claimed |
| CN-1041723-C | Organic salts of N,N'-diacetyl cystine | ASTRA AB (SE) | 1999-01-20 | — | — | CN | claimed |
| CN-1039586-C | Process for preparing organic salts of N, N' -diacetylcystine | ASTRA AB (SE) | 1998-08-26 | — | — | CN | claimed |
| WO-1997048679-A1 | NEW FORMS OF ORGANIC SALTS OF N'N-DIACETYLCYSTINE | ASTRA AKTIEBOLAG (PUBL) (SE) | 1997-12-24 | — | — | WO | claimed |
| CN-1094715-A | N, the organic salt of N ＇-diacetyl Gelucystine | ASTRA AB (SE) | 1994-11-09 | — | — | CN | claimed |
| CN-1073683-A | Organic salts of N, N' -diacetylcystine | ASTRA AB (SE) | 1993-06-30 | — | — | CN | claimed |
| WO-1993001817-A1 | ANTIVIRAL COMPOSITIONS COMPRISING FUSIDIC ACID, L-ASCORBIC ACID AND SALICYLIC ACID AND DERIVATIVES | SSALI CHARLES LWANGA (GB) | 1993-02-04 | — | — | WO | claimed |
| US-4086340-A | ANTIBIOTIC; ANIMAL GROWTH PROMOTER | BAYER AKTIENGESELLSCHAFT (DT) | 1978-04-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | GABBR2 1318/4885GABBR1 1030/4885TAAR1 199/4885 |
| US-20230372492-A1 | DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME | GFPT1, PHPT1, SLC2A1 | GABBR2 4098/4885GABBR1 3576/4885TAAR1 4381/4885 |
| US-20120190680-A1 | Heteroaryl Amide Analogues | P2RX3, P2RX2, ADORA2A | GABBR2 309/4885GABBR1 296/4885TAAR1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.